Abstracts Archive - Page 9 of 2616 - ACR Meeting Abstracts

Abstract Number: 135 • 2026 Pediatric Rheumatology Symposium
The Blood-CSF-Barrier in SLE: Volume and Blood Flow of the Choroid Plexus and Periventricular Tissue Abnormality Gradients
Mark DiFrancesco, Elizabeth Wilson and Hermine Brunner, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: SLE leads to vascular compromise in multiple organs, including brain, leading to parenchymal infiltration. We have demonstrated increased permeability of the blood-brain-barrier (BBB) in…
Abstract Number: 123 • 2026 Pediatric Rheumatology Symposium
The Details Matter: A Patient Centered Approach to Overcoming Barriers in a Pediatric to Adult Rheumatology Transition Clinic
Chrisana Pokorny¹ and Bethany Marston², ¹University of Rochester, Webster, NY, ²University of Rochester, Rochester, NY
Background/Purpose: Structured transition programs from pediatric to adult care improve adherence to visits and treatment, patient satisfaction, quality of life, and disease-specific outcomes2. The GotTransition3…
Abstract Number: 027 • 2026 Pediatric Rheumatology Symposium
An Examination of Brain-age-related Deviations from Normative Neurodevelopmental Trajectory in Children with Childhood-Onset Systemic Lupus Erythematosus
Josephine Machado¹, Diana Valdes Cabrera², Helen Branson³, Adrienne Davis³, Linda Hiraki², Asha Jeyanathan⁴, Deborah Levy², Lawrence Ng⁵, Birgit-Ertl Wagner³ and Andrea Knight⁶, ¹University of Toronto, Woodbridge, ON, Canada, ²The Hospital for Sick Children, Toronto, ON, Canada, ³The Hospital for Sick Children, ⁴Hospital for Sick Children, ON, Canada, ⁵The Hospital for Sick Children, Toronto, Canada, Toronto, ON, Canada, ⁶Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Neuroinflammation is considered to be a major factor in brain-aging—a decline in the structure and function of the brain with age. Presentation of childhood-onset…
Abstract Number: 013 • 2026 Pediatric Rheumatology Symposium
Kikuchi-Fujimoto’s Disease in Systemic Lupus Erythematosus: Single-center Experience
Areum Shin¹, Seonyoung Kang², Doo Ri Kim², Soyeon Kim², Seulkee Lee³, Jaejoon Lee¹, Jihyun Kim³, Heeyeon Cho³, Yae-Jean Kim⁴, Hoon-Suk Cha¹ and Kangmo Ahn¹, ¹Samsung Medical Center, Seoul, ²Samsung Medical Center, Gangnam-gu, Seoul, ³Samsung Medical Center, Sunkyunkwan University School of Medicine, Seoul, ⁴Samsung Medical Center, Gangnam District, Seoul
Background/Purpose: Kikuchi-Fujimoto disease (KD), also known as histiocytic necrotizing lymphadenitis, is a self-limited disease of unknown etiology. An association between KD and systemic lupus erythematosus…
Abstract Number: 001 • 2026 Pediatric Rheumatology Symposium
Longitudinal Cardiovascular Profiles of Youth with Childhood-onset Systemic Lupus Erythematosus
Joyce Chang¹, Gabrielle Alonzi², Michael Ferguson³, Andrea Knight⁴, Jane Newburger⁵, Pamela Weiss⁶, Mary Beth Son² and Karen Costenbader⁷, ¹Boston Children's Hospital, Newton, MA, ²Boston Children's Hospital, Boston, MA, ³Boston Children's Hospital, MA, ⁴Hospital for Sick Children, Toronto, ON, Canada, ⁵Boston Childen's Hospital, Boston, MA, ⁶Childrens Hospital of Philadelphia, Philadelphia, PA, ⁷Brigham and Women's Hospital/ Harvard Medical School, BOSTON, MA
Background/Purpose: The cumulative impact of childhood-onset systemic lupus erythematosus (cSLE) on cardiovascular damage begins at disease onset. We sought to characterize longitudinal cardiovascular profiles of…
Abstract Number: 061 • 2026 Pediatric Rheumatology Symposium
Impacts of Social Drivers of Health on Outcomes for Patients with Pediatric Systemic Lupus Erythematosus
Julia Harris¹, Susan Parish², Michael Holland³, Leslie Favier⁴, Emily Fox³, Maria Ibarra³, Jordan Jones³, Cara Hoffart³ and ashley cooper³, ¹Children's Mercy Kansas City, Overland Park, KS, ²Children's Mercy Kansas City, ³Children's Mercy Kansas City, Kansas City, MO, ⁴Children's Mercy Kansas City, Leawood, KS
Background/Purpose: Improving outcomes for children with systemic lupus erythematosus (SLE) is imperative given the morbidity associated with this disease and the significant disparities. Social drivers…
Abstract Number: 116 • 2026 Pediatric Rheumatology Symposium
Pilot of Adalimumab Withdrawal (PAW): Preliminary Analysis of Feasibility and Acceptability of Self-Collected Capillary Blood Samples
Ruud Verstegen¹, Alicia Iizuka², Chetna Godiwala³, Matthew Iozzio⁴, Melanie Kohlheim⁵, Karin Park⁶, Alan Russell⁷, marc Sudman⁸, Anna Sutton⁹, Erin Balay-Dustrude¹⁰, jennifer Cooper¹¹, Joanne Drew¹², A. Carmela Sagcal-Gironella¹³, Y. Ingrid Goh¹⁴, Olha Halyabar¹⁵, Kyle McBrearty¹⁶, L. Nandini Moorthy¹⁷, Amanda Nowakowski¹⁸, Ryan Oakes¹⁹, Edward oberle²⁰, Mary Ellen Riordan¹³, Marinka twilt²¹, Christina Varghese²² and Daniel Horton²³, ¹The Hospital for Sick Children, Toronto, ON, Canada, ²Rutgers Center for Pharmacoepidemiology and Treatment Science, North Brunswick, NJ, ³Duke Clinical Research Institute, ⁴Rutgers Center for Pharmacoepidemiology and Treatment Science, ⁵Self, Granville, OH, ⁶Childhood Arthritis and Rheumatology Research Alliance, ⁷Duke Clinical Research Institute, NC, ⁸Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁹University of Washington, Woodinville, WA, ¹⁰University of Washington, Seattle, WA, ¹¹University of Colorado, Department of Pediatrics, San Francisco, CA, ¹²Nationwide Childrens' Hospital, Columbus, OH, ¹³Hackensack University Medical Center, Hackensack, NJ, ¹⁴The Hospital for Sick Children, ¹⁵Boston Children's Hospital, ¹⁶Boston Children's Hospital, Boston, MA, ¹⁷Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ¹⁸Joseph M. Sanzari Children's Hospital, Hackensack Meridian Health, ¹⁹University of Colorado School of Medicine, Denver, CO, ²⁰Divsion of Rheumatology, Department of Pediatrics, Nationwide Children's Hospital, Columbus, OH, USA, Columbus, OH, ²¹Alberta Children’s Hospital, ²²Rutgers Robert Wood Johnson Medical School, ²³Rutgers Robert Wood Johnson Medical School, Rutgers Center for Pharmacoepidemiology and Treatment Science, New Brunswick, NJ
Background/Purpose: Strategies to facilitate blood collection outside of clinical spaces may enhance the participation and satisfaction of participants in clinical and translational research studies. We…
Abstract Number: 126 • 2026 Pediatric Rheumatology Symposium
Unmet Social Needs in Pediatric Rheumatic Disease: A Study of Disparities
Hana Moosa¹, Kristina Ciaglia², Yuhan Ma³ and Elizabeth Sloan¹, ¹UT Southwestern, TX, ²UT Southwestern, Dallas, TX, ³Texas Scottish Rite for Children, TX
Background/Purpose: Children with rheumatic diseases often face social determinants of health (SDoH) that affect access and outcomes, yet data in pediatric rheumatology remain limited. We…
Abstract Number: 132 • 2026 Pediatric Rheumatology Symposium
AI-Assisted Body-Region Recognition for Localized Scleroderma: the 1st Step in Automated LoSCAT scoring
Yuanyuan Cao¹, Chongyue Zhao¹, Elena deRosas², Yiwen Zhang³, Wei Chen¹, Kathryn Torok² and Claire Ding⁴, ¹Department of Pediatrics, University of Pittsburgh School of Medicine, UPMC Children’s Hospital of Pittsburgh, ²University of Pittsburgh, Pittsburgh, PA, ³Department of Statistics, University of Pittsburgh, ⁴Winchester Thurston School
Background/Purpose: Localized scleroderma (LS) is a chronic inflammatory skin disorder that can cause functional and cosmetic impairment, especially in children. The Localized Scleroderma Cutaneous Assessment…
Abstract Number: 121 • 2026 Pediatric Rheumatology Symposium
Representation of Skin of Color Among Pediatric Images in ACR Image Library
Brittany Ashe¹, Jonathan Li¹ and Samuel Gagne², ¹Division of Rheumatology, Department of Pediatrics, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA, ²Children's Hospital of Pittsburgh - University of Pittsburgh Medical Center, Pittsburgh, PA
Background/Purpose: Childhood onset rheumatic diseases are rare and potentially life-threatening. Skin rash may be one of the first outward signs that can signal disease and studies have demonstrated that there are disparities in clinicians’…
Abstract Number: 039 • 2026 Pediatric Rheumatology Symposium
Single-center Experience of Voclosporin Use for Pediatric Lupus Nephritis
Ran Hazan¹, Nazlican Civilibal², Kevin Baszis¹ and Tarin Bigley², ¹Washington Univ in St. Louis School of Medicine, Pediatric Rheumatology, st louis, MO, ²Washington Univ in St. Louis School of Medicine, Pediatric Rheumatology
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous disease, and pediatric lupus nephritis (LN) is a severe manifestation affecting 50-60% of children with SLE, contributing…
Abstract Number: 124 • 2026 Pediatric Rheumatology Symposium
Patient perspectives, barriers, and next steps in a health care transition clinic for pediatric to adult rheumatology
Clare Peckenpaugh¹, Echo Warner², Tressie Rollins³, Sarah Wallgren³, Suzy Richins³, Kathy Sward³, Aimee Hersh¹ and Rebecca Overbury¹, ¹University of Utah, Salt Lake City, UT, ²University of Utah College of Nursing; Huntsman Cancer Institute, Salt Lake City, UT, ³University of Utah, UT
Background/Purpose: The ACCORD clinic (adult center for childhood onset rheumatic disease) is an experimental rheumatology clinic focused on integrating Health Care Transition (HCT) to prepare…
Abstract Number: 128 • 2026 Pediatric Rheumatology Symposium
Trends in Medicaid Enrollment Churn Among Children with Rheumatic Disease Diagnoses, 2018-2023
Mia Chandler¹, Matt Hall², Jay Berry³, Valentina Ferrer Valencia³, Mindy Lo⁴, Mary Beth Son⁴ and Valerie L. Ward³, ¹Wake Forest University School of Medicine, Charlotte, NC, ²Children's Hospital Association, ³Boston Children's Hospital, ⁴Boston Children's Hospital, Boston, MA
Background/Purpose: : Medicaid is critical for uninterrupted access to high value care. Considering recent and ongoing changes in Medicaid federal policy, it is critical to…
Abstract Number: 081 • 2026 Pediatric Rheumatology Symposium
Therapeutic Drug Monitoring in Pediatric Rheumatology: A Survey of Providers in North America
A. Carmela Sagcal-Gironella¹, Rachel Randell², Hermine Brunner³, Ellen Go⁴, Anita Siu⁵, Ruud Verstegen⁶ and Marietta DeGuzman⁷, ¹Hackensack University Medical Center, Hackensack, NJ, ²Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Emory University/Children Healthcare of Atlanta, GA, ⁵Rutgers University, Ernest Mario School of Pharmacy and Jersey Shore University Medical Center and K. Hovnanian Children's Hospital, Piscataway, NJ, ⁶The Hospital for Sick Children, Toronto, ON, Canada, ⁷Baylor College of Medicine, Houston, TX
Background/Purpose: Therapeutic drug monitoring (TDM) can optimize patient outcomes in pediatric rheumatology, but its use is not standardized. This study aimed to explore TDM practice…
Abstract Number: 130 • 2026 Pediatric Rheumatology Symposium
Resilience, Cumulative Social Disadvantage, and Disease Activity in Juvenile Idiopathic Arthritis (JIA)
William Soulsby¹, John Boscardin¹, Andrea Knight², Daniel Horton³, Karine Toupin-April⁴ and Emily von Scheven¹, ¹UCSF, ²Hospital for Sick Children, Toronto, ON, Canada, ³Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ, ⁴University of Ottawa
Background/Purpose: Cumulative social disadvantage has been associated with persistent disease activity among children with juvenile idiopathic arthritis (JIA). Resilience is defined as the ability to…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].